WO1993011657A2 - The use of psoralen compounds to inhibit restenosis following angioplasty - Google Patents

The use of psoralen compounds to inhibit restenosis following angioplasty Download PDF

Info

Publication number
WO1993011657A2
WO1993011657A2 PCT/US1992/010982 US9210982W WO9311657A2 WO 1993011657 A2 WO1993011657 A2 WO 1993011657A2 US 9210982 W US9210982 W US 9210982W WO 9311657 A2 WO9311657 A2 WO 9311657A2
Authority
WO
WIPO (PCT)
Prior art keywords
patient
blood
photopheresis
psoralen
affected tissue
Prior art date
Application number
PCT/US1992/010982
Other languages
French (fr)
Inventor
Emil Bisaccia
Albert S. Klainer
Original Assignee
Emil Bisaccia
Klainer Albert S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emil Bisaccia, Klainer Albert S filed Critical Emil Bisaccia
Priority to DK93901142T priority Critical patent/DK0661920T3/en
Priority to DE69228952T priority patent/DE69228952T2/en
Priority to EP93901142A priority patent/EP0661920B1/en
Priority to CA002117330A priority patent/CA2117330C/en
Publication of WO1993011657A2 publication Critical patent/WO1993011657A2/en
Priority to GR990401780T priority patent/GR3032388T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones

Definitions

  • arteriosclerosis and atherosclerosis are also particularly useful for the inhibition of restenosis following angioplasty.
  • a method for treating patients following PTCA to prevent or at least inhibit restenosis using a photoactive compound that binds to nucleic acid upon activation by exposure to electromagnetic radiation of a prescribed spectrum, such as ultraviolet light.
  • Psoralen compounds are particularly preferred for this purpose, especially the compound 8-methoxy psoralen -- in which case UVA radiation is preferred for activating said compound.
  • a photoactive compound such as 8- methoxypsoralen is administered to the patient's blood or angioplasty affected tissue, or some fraction thereof, in vitro or in vivo using conventional administration routes.
  • a portion of the patient's blood or affected tissue is then treated (preferably, extracorporeally) using photopheresis, which comprises subjecting the blood or affected tissue to electromagnetic radiation in a wavelength suitable for activating the photoactive compound, such as ultraviolet light, preferably long wavelength ultraviolet light in the wavelength range of 320 to 400 n , commonly called UVA light.
  • the treated blood or affected tissue, or a fraction thereof, is returned to the patient (in the case of extracorporeal photopheresis) or remains in the patient (following in vivo photopheresis).
  • a photoactive compound is first administered to the blood or affected tissue of a patient following PTCA.
  • the photoactive compound may be administered in vivo (e.g. orally, intravenously or intracather) or may be administered in vitro to a portion of the patient's blood
  • the photoactive compound has been administered is treated by subjecting the portion of the blood or affected tissue to photopheresis using said electromagnetic radiation - for example, ultraviolet light.
  • the photopheresis step is preferably carried out in vitro using an extracorporeal photopheresis apparatus.
  • the photopheresis step in accordance with the present invention may also be carried out in vivo by irradiating the patient in a photopheresis chamber
  • PUVA therapy such as is known in the art for the treatment of psoriasis (PUVA therapy).
  • a presently preferred extracorporeal photopheresis apparatus for use in the methods according to the invention is currently manufactured by Therakos, Inc., Westchester, Pennsylvania under the name UVAR. A description of the
  • Therakos UVAR photopheresis apparatus may be found in U.S. Patent No. 4,683,889, granted to R.L. Edelson on August 14, 1987, the contents of which are hereby incorporated by reference in their entirety.
  • the apparatus includes a pump for removing blood from the patient via a donor needle placed in an appropriate vein of the patient; an irradiation chamber; a radiation source in close proximity to the irradiation chamber and a centrifuge, preferably of the continuous type.
  • the various parts of the apparatus such as tubing collection bags for the blood and the like, which come in contact with the patient's blood or some fraction thereof, are preferably replaceable so that they may be disposed of after each use to prevent the possibility of transmitting blood-borne infections from one patient to others who are subsequently treated with the apparatus.
  • the photopheresis step is carried out in vitro, at least a fraction of the treated blood or affected tissue is returned to the patient following the photopheresis treatment.
  • the treatment method described hereinabove is repeated at an interval of about once per week to about once every four weeks.
  • the treatment methods described herein are administered on two successive days and repeated approximately once per month (ie, the patient preferably receives two treatments every month).
  • the photopheresis treatment described herein is most preferably administered the day following angioplasty, repeated the next day and this two-day treatment is repeated on monthly intervals for a total of five two day treatments over a five month period following angioplasty to prevent or inhibit restenosis.
  • the treatment parameters ie, dosage of the photoactive compound and electromagnetic radiation, periodicity of treatment (e.g., monthly, weekly, etc.) and the number of treatments administered in each period (e.g., twice per month on two successive days) --depending on the condition of the
  • Preferred photoactive compounds for use in accordance with the present invention are compounds known as psoralens (or f urocoumarins) which are described in U.S. Patent No. 4,321 ,919 the disclosure of which is incorporated herein by reference in their entirety.
  • the preferred photoactive compounds for use in accordance with the present invention include the following: psoralen;
  • the most particularly preferred photoactive compound for use in accordance with the invention is 8-methoxy psoralen.
  • the determination of an effective dosage of the psoralen compound is within the ability of persons having ordinary skill in the art.
  • the photoactive compound when administered to the patient's blood or affected tissue in vivo is preferably administered orally, but also can be administered intravenously, intracatheter and/or by other conventional administration routes.
  • the preferred dosage of the photoactive compound is in the range of about 0.3 to about 0.7 mg/kg of body weight although larger or smaller doses may be employed.
  • the photoactive compound is administered in vitro to only a portion of the patient's blood or fraction thereof, it is within the ability of those skilled in the art to calculate a dosage which is equivalent to said range based upon the volume of treated blood or fraction thereof.
  • the photoactive compound When administered orally, the photoactive compound should preferably be administered at least about one hour prior to the photopheresis treatment and no more than about three hours prior to the photopheresis treatment.
  • the timing of administration may be adjusted up or down as needed depending on the b ⁇ oavailability of the photoactive compound, its expected half- life, etc. If administered intravenously or intracatheter, the times would generally be shorter.
  • the photopheresis treatment in the treatment methods according to the invention is preferably carried out using long wavelength ultraviolet light (UVA) at a wavelength within the range of 320 to 400 nm.
  • UVA long wavelength ultraviolet light
  • the exposure to ultraviolet light during the photopheresis treatment preferably has a duration of about three to four hours, although shorter or longer treatment periods may be used if desired.
  • the photoactive compound is 8-methoxypsoralen
  • tissue fraction undergoing treatment tissue fraction undergoing treatment.
  • the described treatment methods act by modifying the patient's immune response to percutaneous transluminal angioplasty.
  • the treatment methods thus are believed to redirect or attenuate physiological response to damage caused by angioplasty that could otherwise result in restenosis.
  • the above-described photopheresis methods may also be used to treat arteriosclerosis and atherosclerosis as a substitute for PTCA.

Abstract

The occurrence of restenosis following percutaneous transluminal coronary angioplasty is prevented or inhibited using a photopheresis treatment method, In accordance with the photopheresis treatment method, a photoactive compound such as 8-methoxypsoralen is administered to the patient's blood or affected tissue, or some fraction thereof, in vitro or in vivo using conventional administration routes. A portion of the patient's blood or affected tissue is then treated (preferably, extracorporeally) using photopheresis, which comprises subjecting the blood or affected tissue to electromagnetic radiation in a wavelength suitable for activating the photoactive compound, such as ultraviolet light, preferably long wavelength ultraviolet light in the wavelength range of 320 to 400 nm, commonly called UVA light. The treated blood or affected tissue, or a fraction thereof, is returned to the patient (in the case of extracorporeal photopheresis) or remains in the patient (following in vivo photopheresis).

Description

THE USE OF PSORALEN COMPOUNDS TO INHIBIT RESTENOSIS FOLLOWING ANGIOPLASTY
FIELD OF THE INVENTION The present invention relates to photopheresis methods for treating
arteriosclerosis and atherosclerosis. These methods are also particularly useful for the inhibition of restenosis following angioplasty.
BACKGROUND OF THE INVENTION
Fanelli, etal., "Restenosis Following Coronary Angioplasty," American Heart Journal, 119. 357-368 (1990), provides a comprehensive review of restenosis after percutaneous transluminal coronary angioplasty (PTCA), including
(i) the mechanisms of angioplasty and restenosis, (ii) clinical aspects of restenosis, (iii) therapeutic trials aimed at decreasing the incidence of restenosis, (iv) management of patients with restenosis and (v) potential future technologies. As reported by Fanelli, et al., the use of PTCA has grown tremendously from a level of approximately 39,000 procedures in 1983 to a number that could exceed 500,000 per year over the next 5 years. Yet despite the tremendous growth and success of PTCA, restenosis remains a major problem, with an overall incidence of 25% to 35%. Various pharmacologic approaches to prevent restenosis have been
tried but, to date, none of them has been demonstrated to significantly alter the rate of restenosis. This has led investigators to attempt non-pharmacolgical approaches (e.g., intravascular stents, laser ballon angioplasty, etc.). These attempts at preventing restenosis have likewise proved unsuccesful according to Fanelli, et al. In view of the above there exists a long felt but unsolved need for a technique to prevent or at least inhibit restenosis following percutaneous
transluminal coronary angioplasty.
BRIEF DESCRIPTION OF THE INVENTION In accordance with the present invention a method has been found for treating patients following PTCA to prevent or at least inhibit restenosis using a photoactive compound that binds to nucleic acid upon activation by exposure to electromagnetic radiation of a prescribed spectrum, such as ultraviolet light. Psoralen compounds are particularly preferred for this purpose, especially the compound 8-methoxy psoralen -- in which case UVA radiation is preferred for activating said compound.
In accordance with the invention, a photoactive compound such as 8- methoxypsoralen is administered to the patient's blood or angioplasty affected tissue, or some fraction thereof, in vitro or in vivo using conventional administration routes. A portion of the patient's blood or affected tissue is then treated (preferably, extracorporeally) using photopheresis, which comprises subjecting the blood or affected tissue to electromagnetic radiation in a wavelength suitable for activating the photoactive compound, such as ultraviolet light, preferably long wavelength ultraviolet light in the wavelength range of 320 to 400 n , commonly called UVA light. The treated blood or affected tissue, or a fraction thereof, is returned to the patient (in the case of extracorporeal photopheresis) or remains in the patient (following in vivo photopheresis). DETAILED DESCRIPTION OF THE INVENTION
According to the claimed methods, a photoactive compound is first administered to the blood or affected tissue of a patient following PTCA. The photoactive compound may be administered in vivo (e.g. orally, intravenously or intracather) or may be administered in vitro to a portion of the patient's blood
which has been removed from the patient by employing conventional blood withdrawal techniques. Psoralen compounds are particularly preferred for this purpose, especially the compound 8-methoxypsoralen -- in which case UVA radiation is preferred for activating said compound. Next, the portion of the patient's blood or affected tissue, to which
the photoactive compound has been administered is treated by subjecting the portion of the blood or affected tissue to photopheresis using said electromagnetic radiation - for example, ultraviolet light. The photopheresis step is preferably carried out in vitro using an extracorporeal photopheresis apparatus. The photopheresis step in accordance with the present invention may also be carried out in vivo by irradiating the patient in a photopheresis chamber
such as is known in the art for the treatment of psoriasis (PUVA therapy).
A presently preferred extracorporeal photopheresis apparatus for use in the methods according to the invention is currently manufactured by Therakos, Inc., Westchester, Pennsylvania under the name UVAR. A description of the
Therakos UVAR photopheresis apparatus may be found in U.S. Patent No. 4,683,889, granted to R.L. Edelson on August 14, 1987, the contents of which are hereby incorporated by reference in their entirety.
The apparatus includes a pump for removing blood from the patient via a donor needle placed in an appropriate vein of the patient; an irradiation chamber; a radiation source in close proximity to the irradiation chamber and a centrifuge, preferably of the continuous type. The various parts of the apparatus, such as tubing collection bags for the blood and the like, which come in contact with the patient's blood or some fraction thereof, are preferably replaceable so that they may be disposed of after each use to prevent the possibility of transmitting blood-borne infections from one patient to others who are subsequently treated with the apparatus.
The exposure of blood or affected tissue to ultraviolet light in a photopheresis apparatus is within the ability of persons having ordinary skill in the
art.
When the photopheresis step is carried out in vitro, at least a fraction of the treated blood or affected tissue is returned to the patient following the photopheresis treatment. Preferably, the treatment method described hereinabove is repeated at an interval of about once per week to about once every four weeks. Most preferably the treatment methods described herein are administered on two successive days and repeated approximately once per month (ie, the patient preferably receives two treatments every month).
In the case when it is desired to prevent restenosis, the photopheresis treatment described herein is most preferably administered the day following angioplasty, repeated the next day and this two-day treatment is repeated on monthly intervals for a total of five two day treatments over a five month period following angioplasty to prevent or inhibit restenosis. In view of the disclosure contained herein, those persons who are skilled in the art will be able to adjust the treatment parameters -- ie, dosage of the photoactive compound and electromagnetic radiation, periodicity of treatment (e.g., monthly, weekly, etc.) and the number of treatments administered in each period (e.g., twice per month on two successive days) --depending on the condition of the
patient and the patient's response to the treatment.
Preferred photoactive compounds for use in accordance with the present invention are compounds known as psoralens (or f urocoumarins) which are described in U.S. Patent No. 4,321 ,919 the disclosure of which is incorporated herein by reference in their entirety.
The preferred photoactive compounds for use in accordance with the present invention include the following: psoralen;
8-methoxypsoralen; 4,5'8-trimethylpsoralen;
5-methoxypsoralen;
4-methylpsoralen;
4,4-dimethylpsoralen;
4-5'-dimethylpsoraien; and 4',8-methoxypsoralen
The most particularly preferred photoactive compound for use in accordance with the invention is 8-methoxy psoralen.
The determination of an effective dosage of the psoralen compound is within the ability of persons having ordinary skill in the art. The photoactive compound, when administered to the patient's blood or affected tissue in vivo is preferably administered orally, but also can be administered intravenously, intracatheter and/or by other conventional administration routes. The preferred dosage of the photoactive compound is in the range of about 0.3 to about 0.7 mg/kg of body weight although larger or smaller doses may be employed. When the photoactive compound is administered in vitro to only a portion of the patient's blood or fraction thereof, it is within the ability of those skilled in the art to calculate a dosage which is equivalent to said range based upon the volume of treated blood or fraction thereof.
When administered orally, the photoactive compound should preferably be administered at least about one hour prior to the photopheresis treatment and no more than about three hours prior to the photopheresis treatment. The timing of administration may be adjusted up or down as needed depending on the bϊoavailability of the photoactive compound, its expected half- life, etc. If administered intravenously or intracatheter, the times would generally be shorter.
The photopheresis treatment in the treatment methods according to the invention is preferably carried out using long wavelength ultraviolet light (UVA) at a wavelength within the range of 320 to 400 nm. The exposure to ultraviolet light during the photopheresis treatment preferably has a duration of about three to four hours, although shorter or longer treatment periods may be used if desired.
The selection of an appropriate wavelength for photopheresis as well as the exposure, depending upon the photoactive compound being employed and the conditions of treatment (e.g., in vivo exposure or in vitro exposure), is within the ability of those skilled in the art in view of the present disclosure.
When the photoactive compound is 8-methoxypsoralen, it is preferred in accordance with the invention to utilize an exposure to UVA radiation of about 2 Joules/meter2 based upon the surface area of the cells in the blood or affected
tissue fraction undergoing treatment.
When the photopheresis treatment according to the invention is carried out in vivo, careful attention should be paid to controlling the maximum radiant exposure so as to avoid unnecessary injury to the patient. Methods for calculating maximum radiant exposure to ultraviolet light are known in the art and, therefore, shall not be described herein.
While the inventors do not intend their invention to be limited by a specific theory of operation, it is believed that the described treatment methods act by modifying the patient's immune response to percutaneous transluminal angioplasty. The treatment methods thus are believed to redirect or attenuate physiological response to damage caused by angioplasty that could otherwise result in restenosis. The above-described photopheresis methods may also be used to treat arteriosclerosis and atherosclerosis as a substitute for PTCA.

Claims

We Claim:
1. The use of a psoralen compound for inhibiting the occurence
of restenosis following percutaneous transluminal angioplasty in a human patient, wherein : a. the psoralen compound is administered to at least a portion of the patient's blood or affected tissue; b. the psoralen compound is activated by exposure to electromagnetic radiation of a prescribed activating spectrum; and c. the resulting treated portion of the patient's blood or affected tissue is presented to the patient's immune system to beneficially alter the patient's response to percutaneous transluminal angioplasty.
2. The use of a psoralen compound in accordance with claim 1 , wherein the psoralen compound is selected from the group consisting of psoralen, 8-methoxypsoraleπ, 4,5'8-trimethylpsoralen, 5-methoxypsoralen, 4-methyipsoralen, 4-,4-dimethylpsoralen, 4-5'-dimethylpsoralen, and 4',8-methoxypsoralen.
3. The use of a psoralen compound in accordance with claim 2, wherein the psoralen compound is 8-methoxypsoralen.
4. The use of a psoralen compound in accordance with claim 3, wherein the dosage of 8-methoxy psoralen is in the range of about 0.3 to 0.7 mg/kg of body weight of the patient.
5. The use of a psoralen compound in accordance with claim 4, wherein steps a-c are carried out on two successive days repeated as needed to maintain inhibition of restenosis.
PCT/US1992/010982 1991-12-17 1992-12-17 The use of psoralen compounds to inhibit restenosis following angioplasty WO1993011657A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DK93901142T DK0661920T3 (en) 1991-12-17 1992-12-17 Use of psoralen compounds to inhibit restenosis after angioplasty
DE69228952T DE69228952T2 (en) 1991-12-17 1992-12-17 USE OF PSORALEN COMPOUNDS TO INHIBIT RESIDUE EQUIPMENT THAT COMES ON VESSEL PLASTICS
EP93901142A EP0661920B1 (en) 1991-12-17 1992-12-17 The use of psoralen compounds to inhibit restenosis following angioplasty
CA002117330A CA2117330C (en) 1991-12-17 1992-12-17 The use of psoralen compounds to inhibit restenosis following angioplasty
GR990401780T GR3032388T3 (en) 1991-12-17 1999-07-07 The use of psoralen compounds to inhibit restenosis following angioplasty.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/809,590 1991-12-17
US07/809,590 US5284869A (en) 1991-12-17 1991-12-17 Photophoresis methods for treating atherosclerosis and for preventing restenosis following angioplasty

Publications (1)

Publication Number Publication Date
WO1993011657A2 true WO1993011657A2 (en) 1993-06-24

Family

ID=25201702

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/010982 WO1993011657A2 (en) 1991-12-17 1992-12-17 The use of psoralen compounds to inhibit restenosis following angioplasty

Country Status (9)

Country Link
US (2) US5284869A (en)
EP (1) EP0661920B1 (en)
AT (1) ATE178757T1 (en)
AU (2) AU3328393A (en)
DE (1) DE69228952T2 (en)
DK (1) DK0661920T3 (en)
ES (1) ES2131572T3 (en)
GR (1) GR3032388T3 (en)
WO (1) WO1993011657A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0579784A1 (en) * 1991-04-09 1994-01-26 Indiana University Foundation Method for preventing restenosis following reconfiguration of body vessels
WO2000041726A2 (en) * 1999-01-15 2000-07-20 Light Sciences Corporation Noninvasive vascular therapy
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284869A (en) * 1991-12-17 1994-02-08 Emil Bisaccia Photophoresis methods for treating atherosclerosis and for preventing restenosis following angioplasty
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) * 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
WO1996040098A2 (en) * 1995-06-07 1996-12-19 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
ATE406909T1 (en) * 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc PREVENTION AND TREATMENT OF PATHOLOGIES ASSOCIATED WITH ABNORMAL PROLIFERATION OF SMOOTH MUSCLE CELLS
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US6008211A (en) * 1995-07-27 1999-12-28 Pdt Pharmaceuticals, Inc. Photoactivatable compounds comprising benzochlorin and furocoumarin
US5902299A (en) * 1997-07-29 1999-05-11 Jayaraman; Swaminathan Cryotherapy method for reducing tissue injury after balloon angioplasty or stent implantation
ATE309807T1 (en) * 1999-09-24 2005-12-15 Vasogen Ireland Ltd COMPOSITION FOR THE TREATMENT OF ATHEROSCLEROSIS CONTAINING A STATIN AND EX-VIVO TREATED BLOOD
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7479123B2 (en) * 2002-03-04 2009-01-20 Therakos, Inc. Method for collecting a desired blood component and performing a photopheresis treatment
US8109981B2 (en) 2005-01-25 2012-02-07 Valam Corporation Optical therapies and devices
WO2007106856A2 (en) * 2006-03-14 2007-09-20 Allux Medical, Inc. Phototherapy device and method of providing phototherapy to a body surface
US20070219600A1 (en) * 2006-03-17 2007-09-20 Michael Gertner Devices and methods for targeted nasal phototherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321919A (en) * 1979-12-11 1982-03-30 Leukocyte Research, Inc. Method and system for externally treating human blood
US4683889A (en) * 1983-03-29 1987-08-04 Frederic A. Bourke, Jr. Method and system for externally treating the blood
US5284869A (en) * 1991-12-17 1994-02-08 Emil Bisaccia Photophoresis methods for treating atherosclerosis and for preventing restenosis following angioplasty
US5116864A (en) * 1991-04-09 1992-05-26 Indiana University Foundation Method for preventing restenosis following reconfiguration of body vessels

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP0661920A4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0579784A1 (en) * 1991-04-09 1994-01-26 Indiana University Foundation Method for preventing restenosis following reconfiguration of body vessels
EP0579784A4 (en) * 1991-04-09 1994-04-06 Indiana University Foundation
WO2000041726A2 (en) * 1999-01-15 2000-07-20 Light Sciences Corporation Noninvasive vascular therapy
WO2000041726A3 (en) * 1999-01-15 2000-11-02 Light Sciences Ltd Noninvasive vascular therapy
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy

Also Published As

Publication number Publication date
DE69228952T2 (en) 1999-10-21
ATE178757T1 (en) 1999-04-15
AU3688497A (en) 1997-12-18
EP0661920A1 (en) 1995-07-12
ES2131572T3 (en) 1999-08-01
US5426116A (en) 1995-06-20
DK0661920T3 (en) 1999-10-25
GR3032388T3 (en) 2000-05-31
AU3328393A (en) 1993-07-19
EP0661920A4 (en) 1995-03-02
EP0661920B1 (en) 1999-04-14
DE69228952D1 (en) 1999-05-20
US5284869A (en) 1994-02-08

Similar Documents

Publication Publication Date Title
US5426116A (en) Photophoresis methods for treating atherosclerosis and for preventing restenosis following angioplasty
EP0579784B1 (en) Method for preventing restenosis following reconfiguration of body vessels
US5514707A (en) Inhibition of smooth muscle cell proliferation by 8-methoxypsoralen photoactivated by visible light
AU670820B2 (en) Method for treating cardiovascular disease through adjunctive photodynamic therapy
Gatzemeier et al. Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer
WO2004110302A3 (en) Methods of delivering anti-restenotic agents from a stent
March et al. 8-Methoxypsoralen and longwave ultraviolet irradiation are a novel antiproliferative combination for vascular smooth muscle.
Hegarty et al. Intra-arterial bromodeoxyuridine radiosensitization of malignant gliomas
CA2117330C (en) The use of psoralen compounds to inhibit restenosis following angioplasty
AU753208B2 (en) The use of psoralen compounds to inhibit restenosis following angioplasty
US5219882A (en) Treatment methods for lymes disease and associated debilitating conditions
EP1218017B1 (en) Combination of a statin and ex-vivo treated blood for treating atherosclerosis
Benstead et al. The effect of combined modality treatment with ionising radiation and TPPS-mediated photodynamic therapy on murine tail skin
US4939167A (en) Use of 5-methoxypsoralen and other furocoumarins as jet lag suppressants
EP1166784B1 (en) Inhibition of vascular restenosis after angioplasty
Sumpio et al. Inhibition of smooth muscle cell proliferation by visible light-activated psoralen.
RU2006231C1 (en) Method for modulating receptor sensitivity
Chang Some new radiotherapeutic approaches and combined protocol trials in the management of malignant gliomas
Debta et al. Photochemotherapy (PUVA): an overview
US20030035813A1 (en) Immunological treatment methods and agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA FI HU JP NO PL RU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2117330

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1993901142

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993901142

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1993901142

Country of ref document: EP